Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the Forecast Period (2025-2034) Due to the Advancements in Targeted Therapies
The follicular lymphoma market is expanding due to several factors. Increased awareness of the disease has led to a higher number of treated cases, contributing to market growth. Additionally, the rising number of clinical trials focused on the different treatment options for follicular lymphoma is a significant driver of its market's expansion.
LAS VEGAS, June 4, 2025 /PRNewswire/ — Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node enlargement, involvement of the bone marrow, and an enlarged spleen, while extranodal manifestations are relatively rare. As of 2024, approximately 35,000 cases of follicular lymphoma have been diagnosed across the 7MM, with both males and females having equal chances of getting the disease.
First-line treatment for follicular lymphoma is well-established, with most patients experiencing durable responses to chemoimmunotherapy (CIT). For patients with localized disease, radiotherapy (RT) alone or in combination with immunochemotherapy is commonly used. RT alone may also be an option for localized relapses.
Learn more about follicular lymphoma treatment guidelines @ Follicular Lymphoma Treatment Market
The follicular lymphoma treatment landscape is broad and continuously evolving, offering multiple options for both newly diagnosed and relapsed/refractory (R/R) cases. Rituximab is the primary treatment option across the lines. It takes the highest market share as well as patient share. The availability of rituximab biosimilars has enhanced accessibility and affordability, maintaining its importance in managing the disease.
Apart from rituximab, GAZYVA/GAZYVARO (obinutuzumab), which, when combined with chemotherapy, has become a key component in first-line treatment strategies. Its effectiveness in both treatment-naïve and relapsed patients has reinforced its central role in clinical practice.
LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy designed to treat adults with R/R follicular lymphoma who have already received two or more prior treatments. Approved in 2023, LUNSUMIO has already captured ~10% patient share in the third line of therapy. Furthermore, the future approvals in earlier lines can boost its market share.
Multiple targeted therapies are making significant contributions. TAZVERIK (tazemetostat), an EZH2 inhibitor, provides a precision medicine approach for patients with specific genetic mutations. BRUKINSA (ibrutinib), a Bruton's tyrosine kinase inhibitor, although primarily approved for other B-cell cancers, also plays a role in follicular lymphoma treatment. Recent approvals have further expanded the arsenal, including EPKINLY/TEPKINLY (epcoritamab), a bispecific antibody targeting CD3 and CD20, as well as CAR T-cell therapies such as KYMRIAH (tisagenlecleucel), YESCARTA (axicabtagene ciloleucel), and BREYANZI (lisocabtagene maraleucel).
These innovative immunotherapies are showing encouraging outcomes, particularly in the R/R setting, and are poised to reshape the therapeutic approach to follicular lymphoma by offering deeper and potentially long-lasting remissions.
Find out more on FDA-approved follicular lymphoma treatment @ Follicular Lymphoma Drugs Market
While ongoing research continues to explore new treatments, many approved therapies are already making a significant impact in the follicular lymphoma treatment landscape.
The forecast period (2024–2034) is expected to bring further advancements, with emerging therapies enhancing existing treatment options. As healthcare spending continues to increase worldwide, the Follicular lymphoma treatment space is anticipated to see a positive shift, with more accessible and effective therapies becoming available to patients in need.
Numerous drugs are currently in development for the treatment of follicular lymphoma, including promising therapies like Zilovertamab Vedotin (Merck Sharp and Dohme), CALQUENCE (acalabrutinib) (AstraZeneca), CTX112 (CRISPR Therapeutics), BGB-16673 (BeiGene), NKTR-255 (Nektar Therapeutics), NVG-111 (NovalGen), AS-1763 (docirbrutinib) (Carna Biosciences), Cemacabtagene Ansegedleucel (ALLO-501) (Allogene Therapeutics), Abexinostat (Xynomic Pharmaceuticals), Golcadomide (Bristol-Myers Squibb), MONJUVI (tafasitamab) (Incyte Corporation), AZD0486 (AstraZeneca), and others, which are set to launch in the 7MM during the forecast period (2024–2034).
Discover which therapies are expected to grab major follicular lymphoma market share @ Follicular Lymphoma Therapy
MONJUVI (tafasitamab) is a humanized monoclonal antibody that targets CD19 and has been engineered with an Fc domain to enhance cytolytic activity. It binds to CD19 proteins on B-cell surfaces, inhibiting their function and triggering cell death. The antibody works through apoptosis and immune-mediated mechanisms, including Antibody-dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-dependent Cellular Phagocytosis (ADCP). In 2010, MorphoSys secured global exclusive rights to develop and commercialize tafasitamab from Xencor, Inc., which developed the Fc-engineered XmAb technology incorporated in the drug.
In December 2024, Incyte presented pivotal findings from the Phase III inMIND trial at the ASH Annual Meeting. The study showed that combining MONJUVI with lenalidomide and rituximab significantly extended progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma, achieving both the primary PFS endpoint and key secondary measures.
AZD0486 (previously TNB-486) is an innovative CD19xCD3 bispecific T-cell engager (TCE) built on an IgG4 backbone. It features a low-affinity anti-CD3 domain designed to limit cytokine release while maintaining robust T-cell-driven cytotoxicity against malignant B cells. The molecule has a silenced Fc region to avoid nonspecific binding and ADCC, while ensuring prolonged half-life for intermittent dosing. AZD0486 is currently in Phase III development for follicular lymphoma.
In November 2024, at ASH 2024, AstraZeneca emphasized its growing hematology pipeline through two oral presentations on AZD0486. Phase I trial data revealed strong efficacy in R/R follicular lymphoma patients, with an overall response rate (ORR) of 96% and a complete response rate (CRR) of 85% at doses of 2.4 mg and higher.
Discover more about drugs for follicular lymphoma in development @ Follicular Lymphoma Clinical Trials
The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years.
DelveInsight's latest published market report, titled as Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the follicular lymphoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The follicular lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Total Diagnosed Incidence Cases of Follicular Lymphoma
Gender-specific Cases of Follicular Lymphoma
Age-specific cases of Follicular Lymphoma
Stage-Specific Cases of Follicular Lymphoma
Grade-Specific Cases of Follicular Lymphoma
Treated Case by Line of Therapy of Follicular Lymphoma
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM follicular lymphoma market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this follicular lymphoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the follicular lymphoma market. Also, stay abreast of the mitigating factors to improve your market position in the follicular lymphoma therapeutic space.
Related Reports
Follicular Lymphoma Epidemiology Forecast
Follicular Lymphoma Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted follicular lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Follicular Lymphoma Pipeline
Follicular Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, among others.
Non-Hodgkin's Lymphoma Market
Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others.
Non-Hodgkin's Lymphoma Pipeline
Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/follicular-lymphoma-market-growth-accelerates-at-a-cagr-of-6-during-the-forecast-period-20252034-due-to-the-advancements-in-targeted-therapies–delveinsight-302472869.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Bybit Card Exclusive: Up to $150 Cashback for Hassle-Free Crypto Spending
DUBAI, UAE, June 6, 2025 /PRNewswire/ — Bybit, the world's second-largest cryptocurrency exchange by trading volume, continues its advance in the crypto payment space with a limited-time campaign for the Bybit Card. Exclusive to new global users of Bybit Card, the new promotion unlocks 10% cashback in its new phase of global expansion. The evolving payment solution eliminates traditional boundaries between digital assets and real-world transactions across markets. Championing crypto freedom, the Bybit Card elevates global convenience and access to premium events and partnerships for the crypto community wherever they are headed. Since celebrating its second anniversary at Bybit's Dubai headquarters, the Bybit Card has unlocked for its users exclusive benefits at the Grand Millennium Hotel in Dubai, and subscription perks for selected AI tools and streaming services. 30-Day Incentive: All Spending Categories Accepted Eligible for global users with more international markets unlocked, the new cashback scheme potentially offers new users an extra $150 in rewards in three simple steps: Applying for a Bybit Card subject to verification and approval Making a first-time deposit equivalent to $100 in value Spending on eligible crypto transactions with the new Bybit Card in the next 30 days for 10% cashback on all eligible transactions Existing Bybit users may also enjoy the same cashback rate up to $75 during the promotional period. Global Accessibility, Unmatched Convenience The Bybit Card serves nearly 2 million users worldwide as a gateway for secure and instant crypto spending at over 90 million global touchpoints. More than a payment tool, it also offers earning opportunities through cashback, rewards, and APR on crypto balances. Incorporating crypto into their way of life in everyday spending, Bybit Card holders can tap or swipe to pay in an instant around the world. Whether they are booking a flight with Cathay Pacific or sipping a cocktail at the Ritz, users stand to get 10% back with the Bybit Card. Key Features: Crypto convenience: seamless spending in crypto, and cash withdrawals from supported ATMs around the world with the physical card available to Mastercard holders. No annual fees and up to 8% APR on balances. Year-round perks: 100% rebates on subscriptions including Netflix, Spotify, and selected AI tools, airport lounge access, and other benefits refreshed seasonally Multi-asset support: USDC, USDT, BTC, ETH, AVAX, and more. The promotion is on a first-come, first served basis for a limited time only. Terms and conditions apply. For full benefits and more exclusive rewards, users may explore: Bybit Crypto Card: Your Ultimate Crypto Debit Card. #Bybit / #TheCryptoArk / #TheBybitCard About Bybit Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at For more details about Bybit, please visit Bybit PressFor media inquiries, please contact: media@ updates, please follow: Bybit's Communities and Social Media Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Xinhua Silk Road: Int'l forum on RCEP local gov't, sister city cooperation opens in E. China's Huangshan
BEIJING, June 6, 2025 /PRNewswire/ — The 2025 RCEP Local Governments and Friendship Cities Cooperation (Huangshan) Forum opened on Thursday in Huangshan City, east China's Anhui Province. Co-hosted by the Chinese People's Association for Friendship with Foreign Countries and People's Government of Anhui Province, the forum gathered some 300 delegates from Regional Comprehensive Economic Partnership (RCEP) member countries to discuss regional cooperation in economy, culture, and sister-city ties under the theme 'Regional Partnership for Common Development'. During the forum, Anhui forged sister province ties with Cambodia's Preah Sihanouk Province and strengthened ties with South Korea's Gangwon Special Self-Governing Province. The Huangshan Initiative launched the RCEP World Heritage Sites Cooperation Alliance. Ten deals covering investment, trade, and cultural exchanges were signed. In addition, the Chinese Academy of International Trade and Economic Cooperation released the 'RCEP Regional Cooperation Development Report 2025,' detailing the pact's implementation results and offering forward-looking cooperation suggestions. Bhokin Bhalakula, president of Thai-Chinese Culture and Economy Association, noted fruitful cooperation under RCEP, including the China–Thailand railway and projects in smart grids and solar PV systems. He proposed building innovative demonstration zones and youth entrepreneurship platforms. Shi Zhongjun, Secretary-General of the ASEAN-China Centre, said RCEP stabilizes the Asia-Pacific economy and injects certainty into global economy. He called for expanded cooperation in digital and green economies, and deeper integration in standards and rules. Multiple sessions were also held, including dialogues on new energy vehicles, photovoltaic supply chains, youth business leaders, agricultural products, e-commerce and overseas Chinese businesses as well as cultural tours. Data showed that Anhui's trade with other RCEP members hit 208.54 billion yuan (about 29.05 billion U.S. dollars) in 2024, up 17.3 percent from that in 2021,accounting for 25 percent of the province's total foreign trade. Trade reached 75.38 billion yuan (approximately 10.5 billion U.S. dollars) in the first four months of 2025, rising 22.8 percent year on year. Since taking effect, the RCEP has spurred regional growth through tariff cuts, streamlined customs clearance, and trade facilitation. Original link:
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Turkish Farmers Leap into Autonomous Tractors with XAG APC2 Autopilot Console
GÖNEN, Turkey, June 6, 2025 /PRNewswire/ — Autonomous tractor operations are gaining ground on Turkey's small and medium-sized family farms, where labor shortages and rising costs remain persistent challenges. Driving this transformation is the increasing uptake of the XAG APC2 AutoPilot Console, which turns even aging tractors into smart, capable field partners. As young people return to agriculture, their push to upgrade existing machinery is making automation more attainable and driving greater efficiency across the sector. Turkey's agricultural landscape is shaped by its vast number of tractors—over 1.5 million, the largest fleet in Europe. The majority of these machines are in the hands of family farms, the backbone of national food production. For these families, each tractor must be a reliable, all-purpose workhorse. But as economic pressures and labor scarcity rise, many have found their trusted machinery in need of an upgrade—not in form, but in function. Gönen, renowned for its expansive paddy fields and rice-growing expertise, is a place where this change is underway. Here, 24-year-old Numan Korkmaz and his family cultivate 140 hectares of rice paddies. Leaning against his red Tümosan tractor, jacket still dusted from morning work, Numan talks about new agricultural technology with the same confidence his parents once reserved for weather and water—unpredictable but essential for survival. 'We need to keep up with modern times in our sector,' he says. For Numan, that meant investing in an XAG APC2 AutoPilot Console—a decision driven by his goal to enable precision farming, achieve centimeter-level accuracy, and ensure orderly, safe work for both daily operations and his family farm's future. Before the APC2, Numan's work demanded constant focus just to keep the tractor straight. Fatigue from long days led to overlapping rows, wasted seeds, and the worry that even a small mistake could cost the season. 'Our work was completely manual,' Numan remembers. The APC2 marked a turning point. The system delivers hands-free steering and precision accuracy for a wide range of tractors, supporting the production of different crops. Instead of worrying about missed patches or crooked lines, Numan now lets the tractor steer itself, even at night or on tough terrain. With tasks such as sowing, fertilizer spreading, or harrowing, Numan is impressed by how APC2's accurate, parallel line keeping has transformed his routine. 'Accuracy and precision are a must for us,' he says. 'I prefer the AB straight line function—it's faster, easier, and more practical.' This new confidence comes from APC2's RTK-based positioning, further supported by IMU (Inertial Measurement Unit) sensors for terrain compensation, which instantly detect ground slope and keep the tractor on course. Overlaps are minimized and every part of land is used efficiently. 'Fuel and time savings are our top priorities, and we are also seeking to reduce excessive inputs,' Numan notes. Such gains are supported by research: Turkish academic studies show GNSS-based guidance reduces field overlaps and input use by 6–10%. Thanks to even greater accuracy with RTK, farmers like Numan are achieving significant savings in fuel and resources, boosting the productivity of each operation. These improvements are especially critical for small and medium farms today. Turkey's annual inflation rate stood at 37.86% in April 2025, according to the Turkish Statistical Institute (TÜİK); persistently high costs, especially for fuel, put intense pressure on farm budgets. Solutions for improving productivity and saving resources have become a necessity, not just an aspiration. For years, these gains seemed out of reach for smallholders, limited by high upfront costs and technical complexity. XAG APC2 has changed the landscape with its all-in-one, waterproof design that integrates navigation and control in a single unit. The system is operated via a smartphone app and requires minimal maintenance. 'If you can use an Android phone, you can use this system,' Numan says, highlighting a key factor in bridging agriculture's generational gap. On a typical day, Numan starts work at 7:30 a.m. and covers nearly 9 hectares using only 30 liters of diesel—a clear demonstration of the savings and peace of mind automation provides. On affordability, he's candid: 'On the contrary, it's actually more costly not to buy it.' As policymakers encourage sustainable progress, real change is unfolding in Turkey's fields, led by forward-thinking farmers like Numan. For him and other smallholders, adopting new technology isn't just about keeping pace—it's about safeguarding the future of their lands. With the next generation stepping into the spotlight, Turkish agriculture is poised to become more productive, resilient, and ready for tomorrow's challenges. Photo – View original content:
